Takeda announces new European head

Takeda Pharmaceutical has announced the appointment of Dr Erich Brunn as chief executive officer of Takeda Pharmaceuticals Europe.

This firm is the company’s wholly-owned subsidiary that controls the oversight of its pan-European sales and marketing efforts.

It supports and leads the overall business activities of the company’s six marketing subsidiaries in the region.

Takeda said it forecasts further growth in Europe as a result of the maximisation of benefits of strategies centred around Takeda Pharmaceuticals Europe.

Dr Brunn has been president of Takeda Pharma, another subsidiary of the firm in Germany, since 2001 and has previously worked in the industry at Upjohn, Pharmacia & Upjohn and Pharmacia in a range of roles.

He also has a doctorate in chemistry.

Yasuchika Hasegawa, president of Takeda, said: “Dr Brunn has a proven track record of success and excellence, which is apparent through the remarkable growth achieved by Takeda Pharma under his leadership.”

He added that the company is confident Dr Brunn will provide Takeda Pharmaceuticals Europe with the same level of success as he takes on the mantle of chief executive at the subsidiary.

In July 2008, Takeda Pharmaceuticals announced its merger with the TAP company in a bid to boost its worldwide operations.